Open enrollment an opportunity to choose Keck Medicine physicians
Open enrollment for benefits-eligible faculty and staff of the University has begun, and personnel are encouraged to choose Keck Medicine of USC providers by signing up for the USC Network Medical Plan. … Read More »
A WEEK OF USC NORRIS CELEBRATIONS
The USC Norris Comprehensive Cancer Center has sponsored a host of activities in October to celebrate the 40th anniversary of its founding as one of the eight original National Cancer Institute Comprehensive Cancer Centers. … Read More »
Gala celebrates USC Norris’ 40 years of progress
By Sara Reeve
Actor-comedian Martin Short was the master of ceremonies for the gala.
The USC Norris Comprehensive Cancer Center has made tremendous advances in the understanding and treatment of cancer during its four decades of existence. At the gala anniversary celebration, “40 Years of Progress – Discovering New Cures,” held on Oct. 11, USC Norris leaders, researchers and supporters came together to honor that advancement.
“This is a very special night for us. We are here to recognize 40 years of movement toward the goal that Ken Norris Jr. set: to end cancer as we know it,” said Carmen A. Puliafito, MD, MBA, dean of the Keck School of Medicine of USC.
The celebration, which raised nearly $2 million to support cancer research at USC Norris, was held at the Westin Bonaventure Hotel in Los Angeles, and attracted 500 guests. Actor/comedian Martin Short served as master of ceremonies, captivating the audience with his witty banter and his personal connection to the cancer center. … Read More »
Cancer-killing cells controlled by epigenetic process, new study shows
By Alison Trinidad
Natural killer (NK) cells in the human body can kill and contain viruses and cancerous tumors. A new study from the Keck School of Medicine of USC describes for the first time how those cells can be manipulated by epigenetics. The discovery, detailed in the Proceedings of the National Academy of Sciences, paves the way for developing more effective cancer drugs. … Read More »